MX2021010837A - Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez. - Google Patents
Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.Info
- Publication number
- MX2021010837A MX2021010837A MX2021010837A MX2021010837A MX2021010837A MX 2021010837 A MX2021010837 A MX 2021010837A MX 2021010837 A MX2021010837 A MX 2021010837A MX 2021010837 A MX2021010837 A MX 2021010837A MX 2021010837 A MX2021010837 A MX 2021010837A
- Authority
- MX
- Mexico
- Prior art keywords
- cell receptors
- tcrs
- antigen
- high avidity
- cell
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 102100022748 Wilms tumor protein Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102100037837 Nucleoporin Nup37 Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 101710127857 Wilms tumor protein Proteins 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816746P | 2019-03-11 | 2019-03-11 | |
| PCT/US2020/021916 WO2020185796A1 (en) | 2019-03-11 | 2020-03-10 | High avidity wt1 t cell receptors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010837A true MX2021010837A (es) | 2021-10-14 |
Family
ID=70155376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010837A MX2021010837A (es) | 2019-03-11 | 2020-03-10 | Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12448430B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3938386A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7611844B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210138043A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113784978B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020237043A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021017703A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132845A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202192252A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286202A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021010837A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109745PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020185796A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3551221T2 (ro) | 2016-12-08 | 2022-04-30 | Immatics Biotechnologies Gmbh | Noi receptori de celule T și imunoterapie cu utilizarea acestora |
| CR20230295A (es) * | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| CN120112559A (zh) * | 2022-10-28 | 2025-06-06 | 百奥赛图(北京)医药科技股份有限公司 | 抗wt1/hla抗体及其应用 |
| WO2025029648A1 (en) * | 2023-07-28 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting loxhd1-associated disease |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| WO2026125718A1 (en) * | 2024-12-13 | 2026-06-18 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| EP1550453B1 (en) | 2002-09-12 | 2015-05-27 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptide preparation |
| US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
| GB0328363D0 (en) | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| EP3760719A1 (en) | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| JP6476182B2 (ja) | 2013-11-22 | 2019-02-27 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 改変された高親和性ヒトt細胞受容体 |
| EP3177314B1 (en) | 2014-08-04 | 2020-10-07 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
| TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗-b7-h4抗體及免疫結合物 |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US11047011B2 (en) | 2015-09-29 | 2021-06-29 | iRepertoire, Inc. | Immunorepertoire normality assessment method and its use |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| AU2017232431A1 (en) | 2016-03-15 | 2018-09-20 | Cancer Research Technology Limited | Chimeric antigen receptor |
| KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| EA201992536A1 (ru) * | 2017-04-24 | 2020-03-05 | Оспедале Сан Раффаэле С.Р.Л. | Tcr и пептиды |
| PL3765615T3 (pl) | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
-
2020
- 2020-03-10 BR BR112021017703A patent/BR112021017703A8/pt unknown
- 2020-03-10 KR KR1020217032466A patent/KR20210138043A/ko not_active Ceased
- 2020-03-10 CN CN202080033281.4A patent/CN113784978B/zh active Active
- 2020-03-10 SG SG11202109745P patent/SG11202109745PA/en unknown
- 2020-03-10 US US17/438,380 patent/US12448430B2/en active Active
- 2020-03-10 EA EA202192252A patent/EA202192252A1/ru unknown
- 2020-03-10 MX MX2021010837A patent/MX2021010837A/es unknown
- 2020-03-10 CA CA3132845A patent/CA3132845A1/en active Pending
- 2020-03-10 AU AU2020237043A patent/AU2020237043A1/en not_active Abandoned
- 2020-03-10 EP EP20716656.2A patent/EP3938386A1/en active Pending
- 2020-03-10 JP JP2021554674A patent/JP7611844B2/ja active Active
- 2020-03-10 WO PCT/US2020/021916 patent/WO2020185796A1/en not_active Ceased
-
2021
- 2021-09-09 IL IL286202A patent/IL286202A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109745PA (en) | 2021-10-28 |
| US12448430B2 (en) | 2025-10-21 |
| IL286202A (en) | 2021-10-31 |
| EP3938386A1 (en) | 2022-01-19 |
| CN113784978B (zh) | 2025-07-25 |
| JP7611844B2 (ja) | 2025-01-10 |
| JP2022525099A (ja) | 2022-05-11 |
| CN113784978A (zh) | 2021-12-10 |
| KR20210138043A (ko) | 2021-11-18 |
| WO2020185796A1 (en) | 2020-09-17 |
| BR112021017703A8 (pt) | 2023-04-18 |
| US20220160764A1 (en) | 2022-05-26 |
| WO2020185796A9 (en) | 2020-10-15 |
| BR112021017703A2 (cg-RX-API-DMAC7.html) | 2021-11-16 |
| AU2020237043A1 (en) | 2021-09-30 |
| EA202192252A1 (ru) | 2021-12-21 |
| CA3132845A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
| WO2020185796A9 (en) | High avidity wt1 t cell receptors and uses thereof | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| CO2019007868A2 (es) | Anticuerpos agonistas anti-icos y sus usos | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
| MX2020008403A (es) | Receptores de celulas t especificos de ciclina a1 y usos de los mismos. | |
| PE20190108A1 (es) | Moleculas de anticuerpo para el tratamiento del cancer | |
| CL2017002237A1 (es) | Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
| CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
| BR112021019365A2 (pt) | Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados | |
| MX2021010543A (es) | Receptores de linfocitos t y metodos de uso de estos. | |
| MX2021010542A (es) | Receptores de linfocitos t y metodos de uso de estos. | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| AR069958A1 (es) | Metodo para producir una proteina heterologa de interes | |
| BR112016010342A2 (pt) | sequência de rna isolada ou sintética, sequência de dna, vetor que permite a expressão de uma sequência de rna, célula que compreende uma sequência de rna, composição que compreende uma sequência de rna, utilização de uma sequência de rna, camundongo transgênico, método que permite avaliar a eficácia cosmética de um composto de teste, e, método que permite avaliar a eficácia terapêutica de um composto de teste | |
| MX2022001207A (es) | Receptores de linfocitos t y metodos de uso de los mismos. | |
| CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza |